Core Viewpoint - Yuanjing Biotechnology is an international high-tech enterprise focused on cell gene editing research and production, aiming to simplify gene editing for global scientific and industrial clients [1]. Group 1: Company Overview - Yuanjing Biotechnology has provided gene editing technology services and related products to over 40 countries worldwide [1]. - The company emphasizes a pragmatic, efficient, honest, and trustworthy approach to serving its clients [1]. Group 2: Promotions and Activities - A customer appreciation lottery event is being held, offering prizes for both new and existing customers [3]. - The grand prize includes 3 SKG neck massagers and customized backpacks, with additional prizes such as umbrellas and desktop fans [4][6]. Group 3: Product Offerings - The CRISPR library offers a coverage rate of over 99% and uniformity of less than 10, facilitating easy screening [8]. - The company provides a full-service package from library construction to bioinformatics data analysis [9]. - Customizable knockout (KO) cell solutions are available, with a rapid construction time of as little as 4 weeks [15]. - The company boasts over 300 cell lines and 6000 successful cases, utilizing its proprietary CRISPR-U™ gene editing technology [17]. Group 4: Special Offers - Various promotional offers include half-price access to the whole genome screening-ready cell pool and discounted functional screening services [10][22]. - Special pricing for wild-type cell culture packages and single clone identification kits is also available [19][22].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 EB 病毒 （EBV）持续感染着超过 90% 的人类，导致传染性单核细胞增多症、自身免疫疾病 （例如多发性硬化症、系统性红斑狼疮） 以及多种上皮细胞或 B 细 胞来源的恶性肿瘤 （例如 鼻咽癌、EBV相关性胃癌、霍奇金淋巴瘤及伯基特淋巴瘤等 ） 。 EB 病毒 （EBV） 是一种致癌病毒，其对 B 细胞 和 上皮细胞 具有高度嗜性，EBV 每年约导致 20 万例癌症，其中 B 细胞癌和上皮细胞癌的数量大致相当。 有研究认为，EBV 利用多种病毒糖蛋白和不同的宿主受体来感染人类 B 细胞和上皮细胞。EBV 对 B 细胞的附着取决于 gp350 与 CR2 （也称为 CD21） 或 CD35 之间的相互作用。gp42 与 gH/gL 形成复合物，与 HLA-II 类分子相互作用，从而触发 EBV 融合素 gB 促使其进入 B 细胞。 EBV 通过其病毒糖蛋白与不同宿主受体的相互作用感染上皮细胞和 B 细胞，但一直不清楚是否存在一种通用受体介导其对这两种主要宿主细胞的感染。 2025 年 6 月 18 日，中山大学肿瘤防治中心 曾木圣 教授、 钟茜 教授团队在国际顶尖学术期刊 ...

Core Viewpoint - The discovery of the Harbin cranium, a well-preserved ancient human fossil, has led to the identification of a potential new hominin lineage named "Dragon Man" (Homo longi), sparking debates in the academic community regarding its classification and relationship with Denisovans [2][4][5]. Group 1: Discovery and Significance - The Harbin cranium is one of the most complete ancient human fossils discovered to date, with uranium-series dating indicating it is no younger than 146,000 years [2]. - The research published in The Innovation journal suggests that the cranium represents a new hominin lineage, "Dragon Man" [2]. - The cranium's discovery and subsequent research provide critical insights into the diversity and evolutionary history of ancient humans in East Asia [7][14]. Group 2: Controversy and Research Findings - There is ongoing debate in the academic community regarding the classification of "Dragon Man," with some researchers suggesting it may belong to the Denisovan lineage due to morphological similarities [4][5]. - The Denisovans are an extinct group identified through genetic evidence, with existing remains being fragmentary and lacking complete morphological features [5]. - Recent ancient DNA studies have provided key insights into the genetic affiliation of the Harbin individual, linking it to the Denisovan lineage and suggesting a close relationship with early Denisovans from Siberia [11][14]. Group 3: Methodology and Technological Advances - The research team successfully extracted ancient DNA from dental calculus of the Harbin cranium, marking a significant advancement in the study of ancient human genetics [6][10]. - The study involved optimizing extraction methods and developing bioinformatics techniques to analyze ancient DNA, overcoming challenges associated with contamination and degradation [10][11]. - The findings highlight the potential of dental calculus as a valuable source for ancient DNA, paving the way for future research in the field [14].

Core Viewpoint - Eli Lilly announced the acquisition of Verve Therapeutics for up to $1.3 billion to enhance its cardiovascular disease treatment pipeline through Verve's gene editing therapies [2]. Group 1: Acquisition Details - Eli Lilly will pay an upfront payment of $1 billion, equivalent to $10.50 per share, plus up to $300 million in potential contingent value rights (CVR) based on the progress of VERVE-102 in clinical trials [12]. - The acquisition aims to leverage Verve's innovative gene editing technology to provide a one-time treatment for cardiovascular diseases, shifting the treatment paradigm from chronic care to a single intervention [9][11]. Group 2: Clinical Trial Insights - Verve's VERVE-102 therapy showed promising results in a Phase Ib clinical trial, with a single infusion leading to a dose-dependent reduction in plasma PCSK9 protein levels and LDL-C, with a 53% average reduction in LDL-C at a 0.6 mg/kg dose [2]. - The therapy targets the PCSK9 gene to lower LDL-C levels, which is crucial for preventing and treating conditions like heterozygous familial hypercholesterolemia (HeFH) [2][13]. Group 3: Company Background and Future Plans - Verve Therapeutics was founded in 2019 by renowned cardiologist Sekar Kathiresan and went public in June 2021, focusing on gene editing technologies for cardiovascular disease prevention and treatment [6]. - The company plans to initiate dosing for the first patient in the Phase II trial of VERVE-102 in the second half of the year and will provide updates on its second clinical project, VERVE-201, aimed at lowering LDL-C [9][12].

2025 年 6 月 16 日，国际顶尖学术期刊 Nature 发布了题为： Transparent peer review to be extended to all of Nature's research papers 的社论。 社论指出，从即日起， Nature 杂志所有新发表的 研究论文 （Research Article） 都将实行 透明同行评审 ，也就是论文都将 附上同行评审报告以及 论文作者的回复 。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 Nature 表示， 这一新政策有助于打开科学的"黑匣子"，揭示研究论文的生成过程，有助于提高科学透明 度，并有助于建立人们对科研过程的信任。 核心政策变更：强制透明同行评审 该社论中写道，一篇发表的研究论文是论文作者与审稿人之间在期刊编辑的引导下进行的广泛谈论交流的 结果。这些讨论可能会持续数月甚至更长时间，旨在提高研究的清晰度以及结论的可靠性。这是一个极其 重要的过程，应当得到更多的认可。 对于处于科研职业生涯早期的研究人员来说，了解这一对其职业发展至关重要的过程具有极大的价值。将 同行评审报告公开也有助于科学传播：这为讲述一个结果是如何得出的，或者一 ...

Core Viewpoint - The research demonstrates that co-delivery of sensor and helper NLR immune receptors can overcome the "Restricted Taxonomic Functionality" (RTF) bottleneck, enabling the reconstruction of immune signaling pathways across distantly related plants [3][4]. Group 1: Research Findings - The study shows that the NLR genes from Solanaceae can function in non-asterid plants when co-delivered with their corresponding NRC-type helper NLR genes [11]. - By transferring the pepper Bs2 gene along with its homologous NRC-type helper NLR gene to rice, the rice was endowed with resistance to the bacterial blight caused by Xanthomonas oryzae pv. oryzicola (Xoc), which it originally lacked [11]. - The molecular mechanism involves the NRC helper protein forming a disease resistance signaling complex upon infection by Xoc, activating downstream immune responses [11]. Group 2: Implications for Agriculture - This breakthrough provides a feasible new strategy for the green control of crop diseases and offers important theoretical and practical demonstrations for future molecular design breeding across multiple species [4][8]. - The transgenic rice carrying the Bs2-NRC complex system showed no significant differences in baseline resistance or field adaptability compared to wild-type rice under non-pathogen-infected conditions, indicating ecological safety of the resistance system [11].

Core Viewpoint - The article discusses the development and potential of protein-targeting degradation technologies, particularly focusing on PROTAC and the newly developed FRTAC, which targets membrane proteins for degradation, showing promise in cancer treatment [1][9]. Group 1: PROTAC and Related Technologies - PROTAC (Proteolysis Targeting Chimeras) utilizes ubiquitin ligases to promote the degradation of pathogenic proteins, making previously "undruggable" proteins viable therapeutic targets [1]. - Several PROTAC drugs are in clinical trials, with Vepdegestrant targeting estrogen receptors recently releasing phase 3 trial results, indicating a potential market entry soon [1]. - Other technologies like LYTAC (Lysosome-Targeting Chimeras) and AUTAC (Autophagy-Targeting Chimeras) have been developed, with LYTAC focusing on secreted and membrane proteins, which constitute about 40% of the human proteome [1]. Group 2: FRTAC Development - A new platform called FRTAC (Folate Receptor-Targeting Degraders) has been developed, which targets membrane proteins for lysosomal degradation using the folate receptor α (FRα) as a transport receptor [3][5]. - FRTAC shows selective internalization in cancer cells overexpressing FRα, effectively transporting target proteins to lysosomes for degradation [5]. - The optimized FRTAC demonstrates sub-nanomolar efficacy in clearing membrane proteins, with its effectiveness dependent on FRα expression and lysosomal activity [5]. Group 3: Applications and Efficacy - The research team constructed FRTACs targeting EGFR and PD-L1, with FR-Ctx inhibiting cancer cell proliferation and FR-Atz enhancing T cell-mediated cytotoxicity against tumor cells [7]. - In mouse models of prostate cancer and humanized melanoma, FR-Atz exhibited strong in vivo PD-L1 targeting degradation efficiency, reprogramming the tumor microenvironment from immunosuppressive to immunostimulatory, outperforming traditional antibody drugs [8]. - Overall, FRTAC can target tumor sites with high affinity and sub-nanomolar activity to degrade membrane proteins, indicating a promising application in cancer therapy [9].

Core Viewpoint - Xaira Therapeutics, an AI drug discovery company, has raised $1 billion in seed funding and aims to revolutionize drug discovery through advanced AI technologies [2] Group 1: Company Overview - Xaira Therapeutics was founded in April 2024 and has a distinguished leadership team, including Nobel laureates and former executives from major pharmaceutical companies [2] - The company has released the largest publicly available Perturb-seq dataset, named X-Atlas/Orion, which supports virtual cell research and enhances drug discovery predictions [3][4] Group 2: Dataset Details - The X-Atlas/Orion dataset includes 8 million cells and covers all protein-coding genes in humans, with over 16,000 unique molecular identifiers from single-cell deep sequencing [4][8] - Perturb-seq technology used in this dataset allows for the simultaneous reading of CRISPR sgRNA genetic perturbations and transcriptomes, revealing dose-dependent genetic effects [4][9] Group 3: Technological Innovations - The FiCS Perturb-seq platform developed by Xaira Therapeutics enables scalable production of perturbation sequencing data, overcoming previous limitations in data generation [8][11] - The platform demonstrates high sensitivity and minimal batch effects, accurately capturing transcriptional changes due to genetic perturbations [8] Group 4: Research Implications - The release of X-Atlas/Orion addresses the challenges of data generation scalability and standardization, facilitating the development of next-generation foundational models in life sciences [11] - The dataset will be shared under a non-commercial license to promote open collaboration in the biotechnology sector, with potential commercial partnerships available [12] Group 5: Future Directions - Xaira Therapeutics plans to expand data generation to include induced pluripotent stem cells and in vivo animal models, aiming for broader applications in AI-driven virtual cell development [20]

Core Viewpoint - The article discusses the significant findings of a research study on long non-coding RNA (lncRNA), specifically the structure of natural RNA nanocages formed by the ROOL RNA, which may have implications for research and therapeutic applications [2][3][11]. Group 1: Research Findings - The study identified two types of natural RNA nanocages formed by the long non-coding RNA ROOL found in bacterial and phage genomes [5]. - The cryo-EM structure revealed that the ROOL RNA forms an octameric nanocage with a diameter of 28 nanometers and an axial length of 20 nanometers, featuring a disordered region in its internal cavity [7]. - The assembly of the nanocage involves a chain exchange mechanism, leading to the formation of a quaternary kissing loop [7]. Group 2: Structural Characteristics - The octameric structure is stabilized by numerous tertiary and quaternary interactions, including the proposed "A-minor staple" [7]. - The isolated ROOL monomer structure was observed at a resolution of approximately 3.2 Å, indicating the complexity of the nanocage assembly [7]. Group 3: Potential Applications - The research suggests that ROOL RNA, when fused with RNA aptamers, tRNA, or microRNA, can maintain its structure and form a nanocage capable of radially displaying cargo [9]. - These findings may lead to the design of novel RNA nanocages for use as RNA carriers in research and therapeutic applications [11].

编译丨王聪 编辑丨王多鱼 排版丨水成文 饶毅 教授是中国科学和教育领域的杰出改革者。1980 年代，饶毅在美国开启职业生涯，2007 年，他辞去美国西北大学终身教职，全职回国，出任北京大学生命 科学学院院长，他引入了多项举措，使中国生命科学研究重焕生机，其中包括采用终身教职制度和同行评审来评估学者的学术成就。如今， 饶毅 卸任了首都医学 大学校长职务，在北京大学负责一个前沿脑科学研究实验室，并担任其他领导职务。 饶毅 一向以直言不讳著称。2008 年，他放弃美国护照，以抗议前总统乔治·W·布什在 9·11 事件后推行的政策。他还在新冠疫情期间批评了美国的政策，并强 烈反对实验室泄漏论。此外，他还是中国人才引进计划的积极倡导者。 2025 年 6 月 17 日，国际顶尖学术期刊 Nature 发布了一篇对 饶毅 教授的专访 ， Nature 向饶毅询问了他如何看待中国在生命科学领域的作用，以及中国怎样 才能成为生物科技超级大国。 饶毅 教授 中国如何能成为生物科技超级大国？ Nature ：根据《自然》指数，中国在生命科学领域的实力不如在物理科学领域。这是为什么呢？ 只要中国没有类似于美国 NIH 这样的机构， ...